SoftBank pauses China investing as crackdown roils portfolio

* Didi, Full Truck Alliance listed during Q1

* China regulatory action has hit valuations

* SoftBank to wait and see on China -Son

* China remains compelling opportunity -executive

* Further upside from India investments listing -executive (Recasts on China crackdown)

By Sam Nussey

TOKYO, Aug 10 (Reuters) - SoftBank Group Corp 9984.T will pause its investing in China as it waits for regulatory action against the country's tech firms to play out, Chief Executive Masayoshi Son said on Tuesday.

"Until the situation is clearer we want to wait and see," Son told a news conference. "In a year or two I believe new rules will create a new situation."

When the Japanese conglomerate posted record annual profit in May executives pointed to further upside from Vision Fund investments such as Chinese ride-hailing firm Didi Global Inc DIDI.N and "Uber for trucks" startup Full Truck Alliance Co Ltd YMM.N .

Those companies listed in New York but Chinese regulatory action has subsequently hammered valuations, underscoring SoftBank's China risk even as the group seeks to reduce dependence on its largest asset, a stake in Chinese e-commerce giant Alibaba Group Holding Ltd 9988.HK .

The shift has cast a chill on SoftBank's investing in China, which makes up about a quarter of its funds' portfolio.

While the crackdown has affected returns expectations, "our broader thesis in China is unchanged: It's still a large, growing and compelling economic opportunity," said Navneet Govil, the chief financial officer of Vision Fund.

The Vision Fund unit on Tuesday posted a first quarter profit of 236 billion yen ($2.14 billion) as gains from listings were offset by falling shares in firms like South Korean e-retailer Coupang Inc CPNG.K .

The China turmoil is clouding the outlook for the group, shares of which have slipped a third from two-decade highs in March amid the completion of a record 2.5 trillion yen buyback. Shares closed up 0.9% ahead of earnings.

"Having a large public portfolio introduces volatility but at the same time it allows us to continue to monetise in a very disciplined manner," said Govil.

Share price weakness and sell-side analyst speculation have driven expectation that a buyback may be imminent.

"Until now we have sold assets and announced a buyback. This time there was no event like that," Son said.

Given the gap between the group's share price and the value of its assets, he added, "I guess we will do a buyback sometime. The timing and size is something we consider daily."


More than two-thirds of the portfolio of the first $100 billion Vision Fund is listed or exited. SoftBank has distributed $27 billion to its limited partners since inception.

Further upside will come from listings by Indian payments firm Paytm and insurance aggregator Policybazaar as well as southeast Asian ridehailer Grab, which is due go public via a blank-cheque company merger, Govil said. SoftBank is also ramping up investing through Vision Fund 2, to which it has committed $40 billion of capital, with the unit making 47 new investments worth $14.2 billion in the April-June quarter alone.

Son said he would invest in the second fund through a scheme using his SoftBank shares as collateral.

In its first quarter, Vision Fund unit gains included 310 billion yen from selling shares in investments such as delivery firm DoorDash Inc DASH.N and ridehailer Uber Technologies Inc UBER.N .

However, group net profit fell 39% to 762 billion yen.

SoftBank has also been betting on publicly listed shares through its SB Northstar trading unit.

It held stakes in firms worth $13.6 billion at the end of June with the portfolio no longer including Microsoft Corp MSFT.O or Facebook Inc FB.O listed three months earlier.

The unit will shrink as SoftBank prioritises the Vision Fund, Son said. ($1=110.3900 yen)
Reporting by Sam Nussey; Editing by Christopher Cushing and Clarence Fernandez and Kirsten Donovan

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.